~~<i id='936B12DFF3'><strike id='936B12DFF3'><tt id='936B12DFF3'><pre id='936B12DFF3'></pre></tt></strike></i>~~

Home» knowledge» entertainment

entertainment

author：leisure time 2025-09-06 08:55:02 Page View：74711

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ASCO: AstraZeneca's hat trick, and palliative care's spotlight
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Ultragenyx gene therapy for rare liver ailment succeeds in late

JonathanWiggs/GlobeStaffUltragenyxsaidThursdayafternoonthatitsgenetherapyforarareliverailment,glycog

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

ADAMFEUERSTEIN/STATYou’rereadingthewebeditionofASCOin30Seconds,STAT’sguidetotheAmericanSocietyofClin